These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 38283805)

  • 1. An overview of multiple myeloma: A monoclonal plasma cell malignancy's diagnosis, management, and treatment modalities.
    Abduh MS
    Saudi J Biol Sci; 2024 Feb; 31(2):103920. PubMed ID: 38283805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Study on Free Light Chain Assay and Serum Immunofixation Electrophoresis for the Diagnosis of Monoclonal Gammopathies.
    Kuriakose E; Narayanan Unni Cheppayil S; Kuzhikandathil Narayanan S; Vasudevan A
    Indian J Clin Biochem; 2019 Jan; 34(1):76-81. PubMed ID: 30728676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Multiple Myeloma - Current Status in Diagnostic Testing and Therapy].
    Kehrer M; Koob S; Strauss A; Wirtz DC; Schmolders J
    Z Orthop Unfall; 2017 Oct; 155(5):575-586. PubMed ID: 28806822
    [No Abstract]   [Full Text] [Related]  

  • 4. Oligoclonal Pattern/Abnormal Protein Bands in Post-Treatment Plasma Cell Myeloma Patients: Implications for Protein Electrophoresis and Serum Free Light Chain Assay Results.
    Singh G
    J Clin Med Res; 2017 Aug; 9(8):671-679. PubMed ID: 28725315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in biology and therapy of multiple myeloma.
    Barillé-Nion S; Barlogie B; Bataille R; Bergsagel PL; Epstein J; Fenton RG; Jacobson J; Kuehl WM; Shaughnessy J; Tricot G
    Hematology Am Soc Hematol Educ Program; 2003; ():248-78. PubMed ID: 14633785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changing paradigms in diagnosis and treatment of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM).
    Ho M; Patel A; Goh CY; Moscvin M; Zhang L; Bianchi G
    Leukemia; 2020 Dec; 34(12):3111-3125. PubMed ID: 33046818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monocyte Subsets and Serum Inflammatory and Bone-Associated Markers in Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma.
    Damasceno D; Almeida J; Teodosio C; Sanoja-Flores L; Mayado A; Pérez-Pons A; Puig N; Arana P; Paiva B; Solano F; Romero A; Matarraz S; van den Bossche WBL; Flores-Montero J; Durie B; van Dongen JJM; Orfao A
    Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33810169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple myeloma. An update on diagnosis and management.
    Kyle RA
    Acta Oncol; 1990; 29(1):1-8. PubMed ID: 2178649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Understanding biology to tackle the disease: Multiple myeloma from bench to bedside, and back.
    Bianchi G; Anderson KC
    CA Cancer J Clin; 2014; 64(6):422-44. PubMed ID: 25266555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma.
    van de Donk NW; Kamps S; Mutis T; Lokhorst HM
    Leukemia; 2012 Feb; 26(2):199-213. PubMed ID: 21852787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MGUS and Smoldering Multiple Myeloma: Diagnosis and Epidemiology.
    Mateos MV; Landgren O
    Cancer Treat Res; 2016; 169():3-12. PubMed ID: 27696254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma.
    Veltri LW; Milton DR; Delgado R; Shah N; Patel K; Nieto Y; Kebriaei P; Popat UR; Parmar S; Oran B; Ciurea S; Hosing C; Lee HC; Manasanch E; Orlowski RZ; Shpall EJ; Champlin RE; Qazilbash MH; Bashir Q
    Cancer; 2017 Sep; 123(18):3568-3575. PubMed ID: 28513828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee.
    Kumar S; Baizer L; Callander NS; Giralt SA; Hillengass J; Freidlin B; Hoering A; Richardson PG; Schwartz EI; Reiman A; Lentzsch S; McCarthy PL; Jagannath S; Yee AJ; Little RF; Raje NS
    Blood Cancer J; 2022 Jun; 12(6):98. PubMed ID: 35768410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Bone marrow plasma concentrations of Dickkopf1 in patients with multiple myeloma].
    Dun XY; Jiang H; Hou J
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2009 Sep; 38(5):453-8. PubMed ID: 19830856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current and emerging treatment options for patients with relapsed myeloma.
    Castelli R; Gualtierotti R; Orofino N; Losurdo A; Gandolfi S; Cugno M
    Clin Med Insights Oncol; 2013 Aug; 7():209-19. PubMed ID: 24179412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoclonal gammopathy and smoldering multiple myeloma: diagnosis, staging, prognosis, management.
    Hillengass J; Moehler T; Hundemer M
    Recent Results Cancer Res; 2011; 183():113-31. PubMed ID: 21509683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple myeloma.
    Harousseau JL; Shaughnessy J; Richardson P
    Hematology Am Soc Hematol Educ Program; 2004; ():237-56. PubMed ID: 15561686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maintenance therapy after allogeneic hematopoietic stem cell transplantation for patients with multiple myeloma.
    Kawamura K
    Int J Hematol; 2023 Aug; 118(2):193-200. PubMed ID: 37060508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of early treatment strategies for high-risk myeloma precursor disease in the future.
    Landgren O; Rajkumar SV
    Semin Hematol; 2011 Jan; 48(1):66-72. PubMed ID: 21232660
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.